Corcept Therapeutics Inc (NASDAQ: CORT) suffers from extremely meaningful negative changes in investment behavior: its longer term price trend turned down, and its shorter term price trend turned down.
Corcept Therapeutics Inc (NASDAQ: CORT) has recently experienced important negative changes in fundamentals. Negative developments: the stock’s power rating fell below 50, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly. Positive development: significant quarterly earnings acceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CORT is expected to continue to be a major Value Builder.
Corcept Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Corcept Therapeutics has a slightly negative Power Rating of 31 and a poor Appreciation Score of 19, producing the Lowest Value Trend Rating.
Recent Price Action
On 4/26/24, Corcept Therapeutics Inc (NASDAQ: CORT) stock enjoyed a large increase of 2.7%, closing at $22.80. NORMAL trading volume accompanied the advance. Relative to the market the stock has been extremely weak over the last nine months but has risen 0.6% during the last week.
Be the first to comment